Biblio print

Tree Display

AceDB Schema

XML Display


Author Report for: Amit T

Contact information:

Amit Tamar
Department of Pharmacology, Technion- Faculty of Medicine, P.O.B. 9697, 31096 Haifa
Phone :
Fax :

    Title: Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease
    Liu W, Lang M, Youdim MB, Amit T, Sun Y, Zhang Z, Wang Y, Weinreb O
    Ref: Neuropharmacology, 109:376, 2016 : PubMed


    Title: Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and beta-amyloid in ageing and Alzheimer's disease
    Weinreb O, Amit T, Bar-Am O, Youdim MB
    Ref: British Journal of Pharmacology, 173:2080, 2016 : PubMed


    Title: Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment
    Weinreb O, Amit T, Bar-Am O, Youdim MB
    Ref: Curr Drug Targets, 13:483, 2012 : PubMed


    Title: From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease
    Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA
    Ref: J Alzheimers Dis, 30:1, 2012 : PubMed


    Title: A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor
    Weinreb O, Amit T, Bar-Am O, Youdim MB
    Ref: International Review of Neurobiology, 100:191, 2011 : PubMed


    Title: Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation
    Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S
    Ref: J Alzheimers Dis, 21:361, 2010 : PubMed


    Title: The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats
    Bar-Am O, Weinreb O, Amit T, Youdim MB
    Ref: Journal of Molecular Neuroscience, 37:135, 2009 : PubMed


    Title: Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs
    Weinreb O, Mandel S, Bar-Am O, Yogev-Falach M, Avramovich-Tirosh Y, Amit T, Youdim MB
    Ref: Neurotherapeutics, 6:163, 2009 : PubMed


    Title: The neuroprotective mechanism of action of the multimodal drug ladostigil
    Weinreb O, Amit T, Bar-Am O, Yogev-Falach M, Youdim MB
    Ref: Front Biosci, 13:5131, 2008 : PubMed


    Title: The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity
    Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, Youdim MB
    Ref: Chemico-Biological Interactions, 175:318, 2008 : PubMed


    Title: Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro
    Bar-Am O, Amit T, Youdim MB
    Ref: Journal of Neurochemistry, 103:500, 2007 : PubMed


    Title: A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing
    Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB
    Ref: FASEB Journal, 20:2177, 2006 : PubMed


    Title: Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
    Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M
    Ref: Neurotox Res, 10:181, 2006 : PubMed


    Title: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition
    Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T
    Ref: Journal of Neuroscience Research, 79:172, 2005 : PubMed


    Title: Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo
    Bar-Am O, Yogev-Falach M, Amit T, Sagi Y, Youdim MB
    Ref: Journal of Neurochemistry, 89:1119, 2004 : PubMed


    Title: PKC and MAP kinase-dependent processing of amyloid precursor protein (APP) by neuroprotective propargylamine cholinesterase inhibitors derived from rasagiline and nonsteroidal anti-inflammatory drugs.
    Youdim MB, Amit T, Avramovich Y, Bar-Am O, Weinstock M, Yogev-Falach M
    Ref: Cholinergic Mechanisms, CRC Press, :353, 2004 : PubMed


    Title: Poster (57) A novel neuroprotective trifunctional cholinesterase inhibitor derivative of the antiparkinson drug, rasagiline, for treatment of dementia and lewy body disease co-morbid with depression
    Youdim MB, Sagi Y, Derigus N, Naoi M, Maruyama W, Amit T, Falash-Yogev M, Weinstock M
    Ref: In: Cholinesterases in the Second Millennium: Biomolecular and Pathological Aspects, (Inestrosa NC, Campos EO) P. Universidad Catolica de Chile-FONDAP Biomedicina:351, 2004 : PubMed


    Title: Amyloid Processing and Signal Transduction Properties of Antiparkinson-Antialzheimer Neuroprotective Drugs Rasagiline and TV3326
    Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M
    Ref: Annals of the New York Academy of Sciences, 993:378, 2003 : PubMed


    Title: The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline
    Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB
    Ref: FASEB Journal, 16:1674, 2002 : PubMed


Send your questions or comments to :
Mail to: Nicolas Lenfant, Thierry Hotelier, Yves Bourne, Pascale Marchot and Arnaud Chatonnet.
Please cite: Lenfant 2013 Nucleic.Acids.Res. or Marchot Chatonnet 2012 Prot.Pept Lett.
For technical information about these pages see:
ESTHER Home Page and ACEDB Home Page
AcePerl Lincoln Stein Home Page

Acknowledgements and disclaimer